The fight against cancer is complex. It’s global. And it’s indisputably expensive.
Budgets can surprise you, and the White House budget proposal for fiscal year 2027 is more surprising than most.
Foundations acquire a critical new role as federal funding for cancer research falters
Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
CEO, The Mark Foundation
Executive chair of the board, The Mark Foundation; Director, Medical University of South Carolina Hollings Cancer Center; Past dean of Medicine, the Medical University of South Carolina
Table of Contents
YOU MAY BE INTERESTED IN
The Mark Foundation for Cancer Research has announced the completion of a merger with the Samuel Waxman Cancer Research Foundation, formalizing a long-standing partnership rooted in a shared commitment to advancing innovative science and bringing new treatments to cancer patients.
Leadership is changing at The Wistar Institute and the Helen F. Graham Cancer Center & Research Institute in the months to come—but the leaders of the two institutions say that this will have little if any effect on the clinical-research collaboration that they have spent the past 15years building (The Cancer Letter, July 12, 2019).
Last week’s issue of The Cancer Letter was dominated by one event: the meeting of the National Cancer Advisory Board, the group of experts which advises and assists the NCI director on the activities of the National Cancer Program.
A public-private effort, spearheaded by NCI Director Anthony Letai, and led by the Foundation for the National Institutes of Health, is working to speed up the development of therapeutic cancer vaccines.
NCI Director Anthony Letai appeared before the National Cancer Advisory Board Committee March 17 to maneuver through thorny topics while reiterating his message of reassurance: Stability. Stability. Stability.
